MedTrace Logo

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

NCT03665285 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2024-03-08

Study results available
· View outcomes & findings →

Summary

This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.

Conditions

Interventions

DRUG

NC318

NC318 is an experimental antibody drug that may make the immune response more active against cancer.

Sponsors & Collaborators

  • NextCure, Inc.

    lead INDUSTRY

Principal Investigators

  • Han Myint, MD · NextCure, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2023-04-11
Completion
2023-04-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03665285 on ClinicalTrials.gov